Browse the evidence

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

Intermittent fasting has cardiometabolic effects in persons with prediabetes and type 2 diabetes.

Healthcare providers may consider intermittent fasting as a potential dietary intervention for patients with prediabetes and type 2 diabetes.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

Semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.

Practitioners can expect significant improvements in metabolic health markers with semaglutide use.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

The use of weight reduction medications as an adjunct therapy alongside dietary, exercise, and behavioral interventions is clearly described in current and future guidelines of the German Obesity Society.

Practitioners should consider weight reduction medications as part of a comprehensive treatment plan.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.

Bariatric surgery is the most durable and effective treatment for severe obesity.

Clinicians should consider bariatric surgery for patients with severe obesity.

Weight loss in individuals with obesity can improve metabolic outcomes.

Practitioners should recognize that while weight loss may improve metabolic health, its effects on mortality are uncertain.

Obesity is a significant modifiable risk factor for atrial fibrillation (AF).

Practitioners should focus on managing obesity to reduce the risk of AF.

The Atrial Fibrillation Better Care pathway emphasizes lifestyle modifications and weight loss strategies for managing AF in obesity.

Implementing lifestyle changes is essential for managing AF in obese patients.

FDA-approved medications such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide have significantly improved weight-loss outcomes.

Practitioners can consider these medications as effective options for weight management.

Semaglutide and tirzepatide achieve weight-loss outcomes comparable to bariatric surgery.

These medications may be considered as alternatives to surgical weight loss options.

Clinical practice guidelines have been updated to reflect the use of glucose-lowering medications for cardiometabolic, renal, and weight goals.

Healthcare providers should integrate these updated guidelines into practice.

GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.

Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.

GLP-1-based therapies elicit a clinically significant reduction in body weight.

Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.

Tirzepatide significantly reduced body weight, BMI, and waist circumference compared with placebo.

Tirzepatide may be an effective treatment for reducing body weight and improving BMI in Chinese adults.

Participants with greater weight reduction showed significantly greater improvements in cardiometabolic markers.

Encouraging weight loss may enhance cardiometabolic health in individuals.

Metabolic syndrome prevalence dropped from 21.6% at baseline to 0% by week 52.

Achieving a normal BMI may eliminate metabolic syndrome risk in individuals.

Tirzepatide reduces appetite and aids in weight reduction management.

Tirzepatide may be effective for patients seeking weight loss.

Ecnoglutide produced mean weight loss of –9.9% (1.2 mg), –13.3% (1.8 mg), and –15.4% (2.4 mg) from baseline at 48 weeks, compared with –0.3% with placebo.

Ecnoglutide is effective for weight loss in Asian populations.

78%–93% of participants achieved ≥5% weight reduction with ecnoglutide.

A significant proportion of users can expect meaningful weight loss.

Weight-reduced patients lost 7.2% total body weight (TBW) versus 10.3% in non-weight-reduced patients (p < 0.001).

Practitioners should consider weight-reduction status when evaluating weight loss outcomes with tirzepatide.

Patients switching from semaglutide due to plateau lost 8.1% TBW versus 2.9% for non-responders (p < 0.001).

Switching from semaglutide may yield different weight loss results based on prior response.